Searched for
WEGOVY SALES DECLINE
CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...- Global Markets | European equities log steep weekly losses with no resolution to MidEast conflictEuropean stocks saw a significant weekly drop Friday. Investors are concerned about growth and inflation due to Middle East conflict disrup...
- Eli Lilly Foundayo weight-loss pill vs Novo Nordisk Wegovy oral obesity treatment tablets: Which medicine is the most prescribed across U.S.?Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
- Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped outNovo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects futur...
- Mounjaro-maker Eli Lilly targets India as global export hub amid booming sales, executive saysEli Lilly aims to establish India as a key hub for its global supply chain. The company plans to export drugs manufactured locally in India...
- NVO stock crashes 14%: Why Novo Nordisk shares are down today? 2026 sales forecast and Eli Lilly competition explainedNVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...
- Intense Lilly, Novo rivalry throws India weight-loss drug race wide openEli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outre...
- Novo Nordisk shares jump 10% after US approves Wegovy pillNovo Nordisk shares jumped 10% on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill, giving the Danish dru...
- Delhi HC allows Dr. Reddy’s to export weight-loss drug semaglutide, calls Novo Nordisk’s case ‘weak’The Delhi High Court declined to stay a single-judge order allowing Dr. Reddy's to export its semaglutide, observing Novo Nordisk's appeal ...
- India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutideThe order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynam...
- Riding high on Wegovy, Novo Nordisk doubled its workforce. Now layoffs loomNovo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's workforce nearly doub...
- Novo Nordisk aims for heavy sales in India with WegovyThe achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescriptio...
- Hims stock tanks over 20% after Wegovy deal collapse — why Novo Nordisk’s breakup over weight loss drugs is shaking up Wall StreetHims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...
- Obesity drug maker Novo Nordisk ousts CEO as competition weighsNovo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity d...
- Novo Nordisk's stock rises as Ozempic beat analysts' expectations in salesIn its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.
- European shares slip but set for weekly gains; Mercedes dropsAutomobile shares led sectoral losses with a 2.9% fall, hurt by a 7.6% drop in Mercedes-Benz after the carmaker cut its full-year profit ma...
- India pharma companies develop versions of Wegovy to get in on weight-loss windfallIndian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight...
Load More
